Arcturus' RNA & mRNA Proprietary Technologies

Technologies

We believe our two proprietary technologies, LUNAR® lipid-mediated delivery and STARR® mRNA Technology, solve major hurdles in RNA medicine development.

LUNAR®

Our first platform is a proprietary lipid-mediated nucleic acid delivery system called LUNAR®. LUNAR® is a multi-component drug delivery system that is versatile and with our library of over 250 proprietary lipids, diverse. Our preclinical studies have shown that formulations can be customized for the indication and target cell type of interest. We have also demonstrated that our formulation process is scalable and reproducible.

Scaler Image
LUNAR® Mechanism of Delivery Video

STARR®

The STARR® Technology platform combines self-replicating RNA with LUNAR®, a leading nanoparticle delivery system, into a single solution to produce proteins inside the human body. The versatility of the STARR® Technology enables it upon delivery into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases. The self-replicating RNA-based prophylactic vaccine triggers rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens. This combination of the LUNAR® and STARR® technology is expected to provide lower dose requirements due to superior immune response, sustained protein expression compared to non-self-replicating RNA-based vaccines and potentially enabling to produce vaccines more quickly and simply.

Scaler Image
STARR® mRNA Technology

LUNAR®-mediated delivery of RNA into cells

LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR® formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR®components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
June 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MORE
June 3, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech
READ MORE
June 4, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Startup Arcturus Pulls in $1.3M in Seed Money amid Renewed Interest in RNAi
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina
READ MORE
August 15, 2013
San Diego upstart acquires RNA tech from cash-strapped Marina Biotech
READ MORE
August 15, 2013
San Diego Life Sciences Roundup: Vical, Fate, Arcturus, and More
READ MORE
July 24, 2025
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
READ MORE
August 11, 2025
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
READ MORE
August 26, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
READ MORE
October 22, 2025
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
READ MORE
October 28, 2025
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
READ MORE
November 4, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
READ MORE
November 10, 2025
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
READ MORE
November 24, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conference
READ MORE
January 8, 2026
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
READ MORE
February 17, 2026
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
READ MORE
March 3, 2026
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
READ MORE
March 5, 2026
Arcturus Therapeutics to Attend Upcoming Investor Conference
READ MORE
April 27, 2026
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
READ MORE
May 7, 2026
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
READ MORE
May 26, 2026
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
READ MORE
July 2, 2026
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
READ MORE
July 20, 2026
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
READ MORE
July 28, 2026
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
READ MORE
August 6, 2026
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
READ MORE
August 31, 2026
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
READ MORE